The stock's fall snapped a three-day winning streak.

Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...

Arish Global Services, the all-in-one solution for web lead generation based in the UK, announced today its partnership with ...

Google has unveiled a detailed whitepaper on the development and functionality of Generative AI agents. Google unveils ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.

This was the stock's third consecutive day of gains.

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (NasdaqGM:VERX) from Outperform to ...

Raymond James downgraded Vertex (VERX) to Market Perform from Outperform without a price target The firm repositioned several ratings ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

A member of the IBD Big Cap 20, Vertex is a top stock to consider after impressive growth last year. VERX stock could present ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.